

# Michael D Leise

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5177343/publications.pdf>

Version: 2024-02-01

60  
papers

2,095  
citations

304602

22  
h-index

233338

45  
g-index

61  
all docs

61  
docs citations

61  
times ranked

3328  
citing authors

#	ARTICLE	IF	CITATIONS
1	Provider Attitudes Toward Risk-Based Hepatocellular Carcinoma Surveillance in Patients With Cirrhosis in the United States. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 183-193.	2.4	15
2	Pseudo-Wilsonian Crisis in a ATP7B Heterozygote. <i>Liver Transplantation</i> , 2022, 28, 131-133.	1.3	0
3	Early thoracentesis correlated with survival benefit in patients with spontaneous bacterial empyema. <i>Digestive and Liver Disease</i> , 2022, 54, 1015-1020.	0.4	1
4	Outcomes following liver transplantation from HCV-seropositive donors to HCV-seronegative recipients. <i>Journal of Hepatology</i> , 2021, 74, 873-880.	1.8	16
5	Liver transplantation for acute liver failure in a SARS-CoV-2 PCR-positive patient. <i>American Journal of Transplantation</i> , 2021, 21, 2890-2894.	2.6	23
6	Incidence and predictors of 30-day hospital readmissions for liver cirrhosis: insights from the United States National Readmissions Database. <i>Annals of Translational Medicine</i> , 2021, 9, 1052-1052.	0.7	19
7	Direct-Acting Antiviral Therapy in Liver Transplant Patients With Hepatocellular Carcinoma and Hepatitis C. <i>Transplantation Direct</i> , 2021, 7, e635.	0.8	4
8	Association of Î± 1 Antitrypsin Phenotype and Development of Advanced Liver Disease and Pulmonary Complications Before and After Liver Transplantation. <i>Transplantation</i> , 2021, 105, 1576-1584.	0.5	4
9	Provider Attitudes and Practice Patterns for Direct-Acting Antiviral Therapy for Patients With Hepatocellular Carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 974-983.	2.4	16
10	MELD-CREGLA: Glomerular Filtration Rate and Mortality on Liver Transplant Waiting List. <i>Hepatology</i> , 2020, 71, 1766-1774.	3.6	40
11	The Current Hepatic Encephalopathy Pipeline. <i>Journal of Clinical and Experimental Hepatology</i> , 2020, 10, 377-385.	0.4	9
12	High prevalence of hepatic steatosis and vascular thrombosis in COVID-19: A systematic review and meta-analysis of autopsy data. <i>World Journal of Gastroenterology</i> , 2020, 26, 7693-7706.	1.4	59
13	Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection Is Associated With Increased Survival in Patients With a History of Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2019, 157, 1253-1263.e2.	0.6	131
14	Liver Transplantation Trends and Outcomes for Hereditary Hemorrhagic Telangiectasia in the United States. <i>Transplantation</i> , 2019, 103, 1418-1424.	0.5	15
15	Abdominal manifestations of hereditary hemorrhagic telangiectasia: a series of 333 patients over 15 years. <i>Abdominal Radiology</i> , 2019, 44, 2384-2391.	1.0	10
16	Direct-Acting Antiviral Therapy Not Associated With Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study. <i>Gastroenterology</i> , 2019, 156, 1683-1692.e1.	0.6	121
17	Incidence and Risk Factors Associated With 30-Day Readmission for Alcoholic Hepatitis. <i>Journal of Clinical Gastroenterology</i> , 2019, 53, 759-764.	1.1	11
18	Indwelling Tunneled Pleural Catheters for Refractory Hepatic Hydrothorax in Patients With Cirrhosis. <i>Chest</i> , 2019, 155, 546-553.	0.4	47

#	ARTICLE	IF	CITATIONS
19	Assessment of the spectrum of hepatic encephalopathy: A multicenter study. <i>Liver Transplantation</i> , 2018, 24, 587-594.	1.3	26
20	Intravenous Bevacizumab for Refractory Hereditary Hemorrhagic Telangiectasia-Related Epistaxis and Gastrointestinal Bleeding. <i>Mayo Clinic Proceedings</i> , 2018, 93, 155-166.	1.4	88
21	Endoscopic management of bile leaks after liver transplantation: An analysis of two high-volume transplant centers. <i>United European Gastroenterology Journal</i> , 2018, 6, 89-96.	1.6	15
22	Risk of Post-transplant Hepatocellular Carcinoma Recurrence Is Higher in Recipients of Livers From Male Than Female Living Donors. <i>Annals of Surgery</i> , 2018, 268, 1043-1050.	2.1	18
23	Relationship between portopulmonary hypertension and splenectomy: Mayo Clinic experience and review of published works. <i>Hepatology Research</i> , 2018, 48, E340-E346.	1.8	5
24	Multicenter Experience using Ledipasvir/Sofosbuvir ± RBV to Treat HCV GT 1 Relapsers after Simeprevir and Sofosbuvir Treatment. <i>Annals of Hepatology</i> , 2018, 17, 815-821.	0.6	4
25	Latest Concepts in Inpatient Hepatic Encephalopathy Management. , 2018, , 77-97.		1
26	Impact of Age on Outcomes in Hospitalized Patients with Hereditary Hemorrhagic Telangiectasia. <i>Advances in Hematology</i> , 2018, 2018, 1-8.	0.6	6
27	The Portosystemic Shunt Syndrome and Role of Shunt Embolization in the Management of Hepatic Encephalopathy. <i>Current Hepatology Reports</i> , 2018, 17, 218-224.	0.4	1
28	Clinical and histopathologic manifestations of solid organ transplantation-associated graft-versus-host disease involving the skin: A single-center retrospective study. <i>Journal of Cutaneous Pathology</i> , 2018, 45, 817-823.	0.7	7
29	Hyponatremia in Cirrhosis: Implications for Liver Transplantation. <i>Liver Transplantation</i> , 2018, 24, 1612-1621.	1.3	22
30	Factors Influencing Surveillance for Hepatocellular Carcinoma in Patients with Liver Cirrhosis. <i>Liver Cancer</i> , 2017, 6, 126-136.	4.2	23
31	Hyponatremia in the perioperative period: When and how to correct. <i>Clinical Liver Disease</i> , 2017, 9, 111-114.	1.0	4
32	Damned if you do, damned if you don't: The evolving story of de novo and recurrent hepatocellular carcinoma amongst those treated with direct-acting antivirals for hepatitis C virus. <i>Liver International</i> , 2017, 37, 809-811.	1.9	2
33	Hepatocellular Carcinoma Is the Most Common Indication for Liver Transplantation and Placement on the Waitlist in the United States. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 767-775.e3.	2.4	112
34	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1814.	2.4	1
35	Reply to: "Interferon-free therapy of hepatitis C during wait list and post transplant risk of hepatocellular carcinoma recurrence". <i>Journal of Hepatology</i> , 2017, 67, 1357.	1.8	0
36	Systematic review of mixed cryoglobulinemia associated with hepatitis E virus infection: association or causation?. <i>Gastroenterology Report</i> , 2017, 5, 178-184.	0.6	49

#	ARTICLE	IF	CITATIONS
37	Evaluation of liver stiffness with magnetic resonance elastography in patients with constrictive pericarditis: Preliminary findings. <i>Journal of Magnetic Resonance Imaging</i> , 2016, 44, 81-88.	1.9	10
38	Embolization of portosystemic shunts for treatment of medically refractory hepatic encephalopathy. <i>Liver Transplantation</i> , 2016, 22, 723-731.	1.3	59
39	Direct acting antiviral therapy and tumor recurrence after liver transplantation for hepatitis C-associated hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2016, 65, 859-860.	1.8	123
40	Reply. <i>Liver Transplantation</i> , 2016, 22, 1736-1737.	1.3	0
41	Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant. <i>Hepatology</i> , 2015, 61, 1880-1886.	3.6	166
42	64-Year-Old Woman With Diarrhea and Increased Abdominal Girth. <i>Mayo Clinic Proceedings</i> , 2015, 90, e35-e39.	1.4	0
43	Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 in patients with cirrhosis. <i>Hepatology</i> , 2015, 62, 1004-1012.	3.6	54
44	Endoscopic ultrasound-guided portal-systemic pressure gradient measurement. <i>Endoscopy</i> , 2014, 46, E654-E656.	1.0	23
45	Effect of the pretransplant serum sodium concentration on outcomes following liver transplantation. <i>Liver Transplantation</i> , 2014, 20, 687-697.	1.3	43
46	Living donor liver transplantation: Alive and well. <i>Liver Transplantation</i> , 2014, 20, 1290-1292.	1.3	1
47	Drug-Induced Liver Injury. <i>Mayo Clinic Proceedings</i> , 2014, 89, 95-106.	1.4	325
48	Rifaximin for Episodic, Overt Hepatic Encephalopathy: The Data are Catching up to Clinical Practice, but Questions Remain. <i>American Journal of Gastroenterology</i> , 2014, 109, 598.	0.2	2
49	Treatment of persistent/medically refractory covert hepatic encephalopathy with the molecular adsorbent recirculating system. <i>Liver Transplantation</i> , 2014, 20, 867-868.	1.3	0
50	Management of Hepatic Encephalopathy in the Hospital. <i>Mayo Clinic Proceedings</i> , 2014, 89, 241-253.	1.4	91
51	Embolization of spontaneous portosystemic shunts for management of severe persistent hepatic encephalopathy. <i>Hepatology</i> , 2014, 59, 735-736.	3.6	18
52	Immunizations in Chronic Liver Disease: What Should be Done and What is the Evidence. <i>Current Gastroenterology Reports</i> , 2013, 15, 300.	1.1	48
53	Complete endoscopic removal of a necrotic spleen (with video). <i>Gastrointestinal Endoscopy</i> , 2012, 75, 694-695.	0.5	0
54	A Revised Model for End-Stage Liver Disease Optimizes Prediction of Mortality Among Patients Awaiting Liver Transplantation. <i>Gastroenterology</i> , 2011, 140, 1952-1960.	0.6	131

#	ARTICLE	IF	CITATIONS
55	IgG4-Associated Cholecystitis: Another Clue in the Diagnosis of Autoimmune Pancreatitis. <i>Digestive Diseases and Sciences</i> , 2011, 56, 1290-1294.	1.1	33
56	Drug therapy: Telaprevir. <i>Hepatology</i> , 2011, 54, 1463-1469.	3.6	6
57	Patients Dismissed From the Hospital With a Diagnosis of Noncardiac Chest Pain: Cardiac Outcomes and Health Care Utilization. <i>Mayo Clinic Proceedings</i> , 2010, 85, 323-330.	1.4	30
58	Rifaximin in Hepatic Encephalopathy: Is an Ounce of Prevention Worth a Pretty Penny?. <i>Gastroenterology</i> , 2010, 139, 1416-1418.	0.6	4
59	Hepatitis C nonresponders: Re-treat or retreat?. <i>Hepatology</i> , 2009, 50, 1307-1309.	3.6	2
60	75-Year-Old Man With Abdominal Pain and Weight Loss. <i>Mayo Clinic Proceedings</i> , 2008, 83, 1161-1164.	1.4	1